Antibody Targeting of Cathepsin S Inhibits Angiogenesis and Synergistically Enhances Anti-VEGF
Claire Ward, Diana Kuehn, Roberta E. Burden et al. · 2010
Read Antibody Targeting of Cathepsin S Inhibits Angiogenesis and Synergistically Enhances Anti-VEGF by Claire Ward, Diana Kuehn, Roberta E. Burden et al. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0012543.txt.
Description
Claire Ward, Diana Kuehn, Roberta Burden and colleagues aimed antibodies at a vessel-feeding enzyme, in a 2010 PLOS ONE paper. Tumors cannot grow without new blood vessels, and blocking vessel growth is a proven cancer strategy. The enzyme cathepsin S helps tumors build those vessels, while the standard anti-VEGF drugs block a different signal, so the two might combine well.
Antibody targeting of cathepsin S inhibited vessel growth and, paired with anti-VEGF treatment, worked better than either alone. Synergy between two vessel attacks could help tumors that escape single drugs. The study supports clinical development of cathepsin S antibodies for cancer.
Catalog record
| CREATOR | Claire Ward, Diana Kuehn, Roberta E. Burden et al. |
|---|---|
| YEAR | 2010 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31 KB |
| LICENSE | Creative Commons Attribution License |
| RIGHTS | CC BY |
| SOURCE | PLOS ONE |
Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0012543